April 30, 2013
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
Re:
|
ADMA Biologics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-186579
|
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise you that as of the date hereof, approximately 1,300 copies of the Preliminary Prospectus dated April 30, 2013 were distributed as follows: approximately 0 to prospective underwriters; approximately 300 to institutional investors; approximately 0 to prospective dealers; and approximately 1,000 to individuals.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
We hereby join in the request of the registrant that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:00 pm Eastern time on April 30, 2013 or as soon thereafter as practicable.
|
Very truly yours,
Oppenheimer & Co. Inc.
BMO Capital Markets Corp.
As Representatives of the severalUnderwriters
|
|||
|
Oppenheimer & Co. Inc.
|
|||
|
By:
|
/s/ Douglas Cameron
|
||
|
Name: Douglas Cameron
|
|||
|
Title: Managing Director
|
|||
|
BMO Capital Markets Corp.
|
|||
|
By:
|
/s/ Lori A. Begley
|
||
|
Name: Lori A. Begley
|
|||
|
Title: Managing Director
|
|||